Andrew Green Sells 6,510 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 6,510 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $27.27, for a total value of $177,527.70. Following the completion of the sale, the senior vice president directly owned 53,133 shares of the company’s stock, valued at $1,448,936.91. The trade was a 10.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Artivion Trading Down 0.1%

Shares of AORT stock opened at $25.59 on Friday. The company has a market capitalization of $1.25 billion, a P/E ratio of -365.52 and a beta of 1.25. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The business’s 50 day moving average is $26.09 and its two-hundred day moving average is $29.21. Artivion, Inc. has a twelve month low of $19.16 and a twelve month high of $48.25.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The business had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Equities analysts forecast that Artivion, Inc. will post 0.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research report on Monday, June 1st. Weiss Ratings downgraded shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Canaccord Genuity Group increased their price objective on shares of Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Wall Street Zen lowered shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price target on shares of Artivion in a research note on Monday, July 20th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and an average target price of $44.83.

Institutional Trading of Artivion

A number of institutional investors and hedge funds have recently bought and sold shares of AORT. BlackRock Inc. purchased a new position in Artivion in the second quarter valued at about $149,965,000. Conestoga Capital Advisors LLC purchased a new stake in shares of Artivion during the 1st quarter valued at about $43,044,000. California State Teachers Retirement System raised its holdings in shares of Artivion by 2,086.7% during the 2nd quarter. California State Teachers Retirement System now owns 1,119,860 shares of the company’s stock valued at $25,163,000 after buying an additional 1,068,647 shares during the period. Summit Partners Public Asset Management LLC acquired a new position in Artivion during the 4th quarter worth approximately $39,401,000. Finally, Invesco Ltd. lifted its position in Artivion by 211.9% during the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after acquiring an additional 748,119 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.